Annovis Bio, Inc. (NYSE:ANVS) CEO Maria-Luisa Maccecchini Buys 18,000 Shares

Annovis Bio, Inc. (NYSE:ANVS) CEO Maria-Luisa Maccecchini acquired 18,000 shares of Annovis Bio stock in a transaction that occurred on Monday, October 11th. The stock was bought at an average price of $27.61 per share, for a total transaction of $496,980.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of ANVS opened at $27.50 on Thursday. Annovis Bio, Inc. has a 12-month low of $4.14 and a 12-month high of $132.00. The company’s 50-day moving average price is $34.63 and its 200 day moving average price is $49.84.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings data on Tuesday, July 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03.

Separately, Maxim Group initiated coverage on shares of Annovis Bio in a report on Friday, October 8th. They issued a “buy” rating and a $70.00 price objective on the stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANVS. US Bancorp DE acquired a new position in Annovis Bio in the 2nd quarter valued at about $43,000. Wells Fargo & Company MN grew its position in Annovis Bio by 2,048.0% in the 2nd quarter. Wells Fargo & Company MN now owns 537 shares of the company’s stock valued at $47,000 after acquiring an additional 512 shares in the last quarter. Northern Trust Corp acquired a new position in Annovis Bio in the 1st quarter valued at about $207,000. National Asset Management Inc. acquired a new position in Annovis Bio in the 2nd quarter valued at about $208,000. Finally, Virtus ETF Advisers LLC acquired a new position in Annovis Bio in the 2nd quarter valued at about $215,000. 15.60% of the stock is owned by institutional investors.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders.

Recommended Story: How do candlesticks reflect price movement?

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.